Clinical trials: Apixaban
Stroke, Systemic Embolism, VTEt and VTEp
Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries
The main purpose is to evaluate the effectiveness of the Eliquis® (apixaban) Prescriber Guide and Patient Alert Card in terms knowledge of the important identified risk of bleeding associated with Eliquis treatment communicated…
- Trial name
- NCT02339818
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, End-stage Kidney Disease
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA) phenprocoumon in patients with NVAF and ESKD…
- Trial name
- AXADIA (NCT02933697)
- Testing
- Apixaban, Phenprocoumon
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Atrial Fibrillation Network
Valve Disease, Heart, Atrial Fibrillation (AF)
Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR
SAFE-HEART is a single-centre, randomized controlled trial comparing the safety and efficiency of Apixaban versus Warfarin in the early period (3 months) after repair or bioprosthetics of the mitral and aortic valve cardiac…
- Conditions
- Valve Disease, Heart, Atrial Fibrillation (AF), Valve Replacement Surgery, Aortic Valve Surgery
- Trial name
- SAFE-HEART (NCT07434661)
- Testing
- Apixaban, Warfarin
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Aortic Valve Replacement, Antithrombotic Therapy
Apixaban for the Prevention of Latent Biological Valve Thrombosis
Background: The optimal antithrombotic strategy early after aortic valve replacement surgery with a biological valve remains controversial due to lack of high-quality evidence.
- Conditions
- Aortic Valve Replacement, Antithrombotic Therapy, Bioprosthetic Valve Thrombosis, Rapid Deployment Valves
- Trial name
- NCT06184113
- Testing
- Aortic valve replacement surgery, Computed tomography, Echocardiography
- Where
- Croatia
- Volunteers
- 166 people
- Sponsor
- Clinical Hospital Centre Zagreb
Deep Vein Thrombosis, Pulmonary Embolism
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- HI-PRO (NCT04168203)
- Testing
- Apixaban 2.5 MG
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Brigham and Women's Hospital
Hemorrhage, Thromboembolism
Apixaban Discontinuation Prior to Major Surgery
The ADIOS study is a prospective, observational study will evaluate one hundred and thirty (130) patients with non-valvular atrial fibrillation who are currently receiving treatment with apixaban as indicated to reduce the risk…
- Trial name
- ADIOS (NCT02935751)
- Testing
- Lab tests for plasma levels of apixaban and anti-10a factor
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Thomas Jefferson University
Venous Thromboembolism
Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS
To assess the real-world safety/effectiveness of Eliquis in Korean venous thromboembolism (VTE) patients and patient characteristics that are associated with bleeding among patients taking Eliquis.
- Trial name
- NCT02546817
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Medical Need of OAC Reversal
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF
- Trial name
- NCT03254147
- Testing
- warfarin, dabigatran, Apixaban
- Where
- Japan
- Volunteers
- 53,969 people
- Sponsor
- Boehringer Ingelheim
Healthy
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily…
- Trial name
- NCT04593784
- Testing
- Ciraparantag, Point-of-Care Coagulometer (investigational device)
- Where
- 3 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.
Deep Vein Thrombosis, Pulmonary Embolism
AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients
The purpose of this study is to investigate safety of apixaban in Japanese acute DVT/PE subjects when symptomatic DVT/PE subjects are treated with 10 mg BID apixaban for 7 days as initial therapy followed by 5 mg BID apixaban for…
- Trial name
- NCT01780987
- Testing
- Apixaban, Unfractionated Heparin (UFH), Warfarin
- Where
- 20 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Pfizer
Atrial Fibrillation
The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study
Old age, less body weight and deteriorated renal function are significant clinical factors for the outcomes of atrial fibrillation- so called 'fragile'- and these are common risk factors in osteoporosis and fracture.
- Trial name
- NCT04198844
- Testing
- warfarin, apixaban
- Where
- South Korea
- Sponsor
- Pfizer
Healthy Volunteer
Bioequivalence Study of Apixaban 5 mg Film-coated Tablets in Healthy Thai Volunteers
The goal of this bioequivalence of two formulations of generic apixaban 5 mg film-coated tablets. Single-dose under fasting conditions and pharmacokinetics will be characterized for a total of 28 healthy adult human subjects.
- Trial name
- NCT06388239
- Testing
- Apixaban 5MG
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- International Bio service
Atrial Fibrillation, Peritoneal Dialysis Complication
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
Introduction: Several randomised controlled trials have demonstrated that novel oral anticoagulants (NOACs) are safer compared to vitamin K antagonists for the management of non valvular atrial fibrillation (NVAF) to prevent…
- Trial name
- APIDP2 (NCT06045858)
- Testing
- Anticoagulation Agents
- Volunteers
- 178 people
- Sponsor
- University Hospital, Caen
COVID-19, SARS-CoV-2
FREEDOM COVID-19 Anticoagulation Strategy
Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era.
- Trial name
- FREEDOM COVID (NCT04512079)
- Testing
- Enoxaparin, Apixaban
- Where
- 21 sites in United States, Brazil and 3 more
- Volunteers
- 3,460 people
- Sponsor
- Valentin Fuster
Patient Engagement, Patient Satisfaction
Alexa, What is Eliquis and Xarelto?
The purpose of this study is to evaluate the effectiveness of providing patient medication education about Eliquis and Xarelto through an Amazon Alexa based voice recording.
- Trial name
- NCT04790773
- Testing
- Amazon Alexa based voice recording patient education
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Hemorrhage, Intracranial Hemorrhages
Restarting Anticoagulation After Traumatic Intracranial Hemorrhage
Primary Objective: To identify the optimal interval to restart oral anticoagulation after traumatic intracranial hemorrhage that will minimize thrombotic events and major bleeding by performing a response adaptive randomized…
- Conditions
- Hemorrhage, Intracranial Hemorrhages, Bleeding, Trauma
- Trial name
- Restart tICrH (NCT04229758)
- Testing
- Anticoagulants
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- University of Texas at Austin
Stroke, Ischemic Stroke
Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay.
- Conditions
- Stroke, Ischemic Stroke, Cerebral Infarction, Atrial Fibrillation
- Trial name
- SPICAF (NCT06486792)
- Testing
- Apixaban, Aspirin
- Where
- France
- Volunteers
- 1,148 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF)
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients With NVAF/ VTE and ESKD on Dialysis
This is a retrospective study of End-Stage Kidney Disease (ESKD) patients on dialysis receiving apixaban or warfarin at Tawam Hospital [a tertiary care hospital in Al Ain, UAE].
- Conditions
- End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
- Trial name
- WARD (NCT06606275)
- Testing
- Apixaban, Warfarin
- Where
- United Arab Emirates
- Volunteers
- 67 people
- Sponsor
- Abu Dhabi Health Services Company